CONNECT WITH US:
Jul 25, 2022 10:00 JST
Source: Novotech Health Holdings Pte Ltd
Novotech's Flexible Work Policy is Finalist in Best Workplace Flexibility Program "Excellence Award 2022"
SYDNEY, AU, Jul 25, 2022 - (ACN Newswire) - Novotech, the leading Asia Pacific biotech specialist CRO with expanded services in the US, has been recognised for its innovative approach to workplace flexibility.
Novotech CEO Dr. John Moller said: "Our flexible workplace design, information technology infrastructure, and flexible resourcing of projects are consistently delivering successful outcomes for our team members, clients, and all stakeholders. We are extremely pleased our workplace flexibility efforts are recognised by the Best Workplace Flexibility Program which has selected Novotech as an Excellence Awardee in 2022."
Novotech Chief People Officer Angela Edwardson said that "over the last 12 months, Novotech has re-imagined what flexible working looks like for teams, clients, and the business. This renewed way of working incorporates flexible, remote, and in-office working options and aims to create a dynamic business environment and trusted culture. Team members can determine and apply the most effective way to work, unlocking the maximum value of their talent to benefit all stakeholders."
Some of the new flexible working policies include:
- FlexLocation: Work from home, office or other suitable location.
- FlexTime: Flexible start/finish times
- FlexBreak:Bbreaks during the day for wellbeing or other commitments.
- FlexHours: An adjustment to contracted hours, either permanently or temporarily (ie: full-time to part-time).
- FlexPlace: The option to work at other Novotech offices or cities/countries without a Novotech office temporarily.
- FlexStudy: A combination of Flex options and/or leave to meet study commitments.
- FlexHolidays: The option to select alternate dates in lieu of allocated celebration/public holidays.
- FlexLeave: Leave can be taken by the hour and in combination with other leave types and flexible options.
- FlexTimeout: Extended unpaid leave to pursue and interest, relax or attend to caring responsibilities
- FlexPersonal: A combination of day-to-day and/or planned options.
"Already 17 team members have used or are planning to use FlexPlace in 2022," said Edwardson. "Novotech has a large cohort of expatriate workers, and our new addition of FlexPlace supports them to re-connect with their families and friends or travel while still meeting their working requirements."
Novotech's Asia-Pacific and US teams support cost-effective expedited clinical research with world-class data and the most advanced technology including solutions that enable acceleration of clinical trials across the regions.
Novotech now has a workforce of ~2,500 clinical trial professionals across Australia, South Korea, Greater China, Southeast Asia, India, South Africa and the US.
Asia-Pacific offers a compelling solution for expedited clinical trials especially in oncology with its vast patient populations, less competitive clinical trial landscape, and world-class KOLs, in addition regulatory reforms, such as those in China, have accelerated approval processes.
The expansion into the US provides US-based expertise and infrastructure for our US clients wanting trials in APAC and the US, and for our APAC clients wanting US clinical programs.
Novotech is the leading Asia-Pacific biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427
Sectors: BioTech, Healthcare & Pharm, Clinical Trials
Copyright ©2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Fujitsu Spain receives 9th award of the "Fundación Consejo España-Japón" (Spain-Japan Foundation)
Oct 05, 2022 14:13 JST
Eisai Completes Construction of Its New Injection/Research Building at Kawashima Industrial Park in Japan
Oct 04, 2022 16:44 JST
MHI Group Delivers Two Large-Capacity Centrifugal Chillers for Singapore's Marina Bay District Cooling System
Oct 04, 2022 11:58 JST
Rinnai and Toyota Start Exploring Hydrogen-Powered Cooking Methods
Oct 04, 2022 11:02 JST
Neste, Idemitsu Kosan, CHIMEI and Mitsubishi Corporation join forces to create a renewable plastics supply chain
Oct 03, 2022 17:11 JST
Rovanpera crowned youngest ever champion with TOYOTA GAZOO Racing
Oct 03, 2022 11:15 JST
Hitachi Astemo develops Steer-by-Wire prototype with advanced steering and failsafe function
Oct 03, 2022 09:30 JST
NEC Announces Progress on Environmental, Social and governance initiatives to support sustainable growth for the company and society
Sep 30, 2022 14:48 JST
Fujitsu highlights technologies to realize its vision for a sustainable world at CEATEC 2022
Sep 30, 2022 11:43 JST
Olympus Launches THUNDERBEAT Energy Device for Open Surgery
Sep 30, 2022 11:00 JST
Dell Technologies and Fujitsu Collaborate to Accelerate Open RAN Global Adoption
Sep 30, 2022 10:41 JST
MHI: Advanced light water reactor "SRZ-1200"
Sep 29, 2022 17:55 JST
AEON and CJPT Begin Logistics Improvement in Kyushu
Sep 29, 2022 17:20 JST
NTT DOCOMO and NEC Reduce Power Consumption for 5G SA Core by an Average of 72% using AWS Graviton2, Followed by a Successful Onboarding of 5G SA Core on Hybrid Cloud
Sep 29, 2022 16:50 JST
NEC and Red Hat Expand Global Collaboration to Drive IT Modernization and Digital Transformation
Sep 29, 2022 16:23 JST
NTT DOCOMO to Add Fourth Virtualized Base Station to Open RAN Verification Environment
Sep 29, 2022 11:16 JST
NEC Launches Open RAN cloud-native virtualized software suite to extend the NEC Open Networks best of breed ecosystem
Sep 29, 2022 09:11 JST
MHI and Institut Teknologi Bandung Launch Joint R&D for Ammonia-Fired Power Generation Using Gas Turbines in Indonesia
Sep 28, 2022 16:05 JST
Eisai's Lecanemab Confirmatory Phase 3 Clarity AD Study Met Primary Endpoint
Sep 28, 2022 15:15 JST
NEC Launches North American Innovation Hub for Open RAN
Sep 28, 2022 14:50 JST
More Latest Release >>
Novotech presented with Cell & Gene Excellence Award 2022 at 6th Cell & Gene Therapy World Asia Conference
September 15 2022 17:00 JST
Novotech at ESMO Congress 2022 - New Data Shows 100% Oncology Trials Growth in APAC
September 05 2022 18:00 JST
APAC Attracts 50% of Global Clinical Trials According to New GlobalData Report
September 02 2022 14:00 JST
Novotech and Endpoints Present "Evolution of Cell & Gene Therapy in China: The Case for Universal CAR-T"
July 18 2022 16:00 JST
Novotech Client SK bioscience Achieves SKYCovione(TM) COVID-19 Vaccine Approval in Korea
July 13 2022 14:30 JST
Novotech Receives "Best Biologics CRO Award 2022" at Korea Bioprocessing Excellence Awards 2022
June 29 2022 07:00 JST
Novotech Receives CRO Leadership Award for Exceeding Customer Expectations
June 23 2022 08:00 JST
SINGAPORE ANNUAL MEETING: DIA and CoRE Gathering Key Healthcare Experts in Neutral Forum to Discuss Regulatory News and Drug Development
June 15 2022 08:30 JST
Novotech's APAC and USA Leadership Teams at BIO 2022
June 14 2022 22:00 JST
Novotech Sponsors Endpoints ASCO 2022 Expert Panel on Accelerating Oncology Clinical Trials in China
June 06 2022 18:00 JST
More Press release >>